Form 8-K - Current report:
SEC Accession No. 0001628280-25-015057
Filing Date
2025-03-27
Accepted
2025-03-27 07:39:25
Documents
15
Period of Report
2025-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adc-20250327.htm   iXBRL 8-K 23973
2 EX-99.1 adct-20241231pressrelease.htm EX-99.1 183860
6 image_4a.jpg GRAPHIC 20773
  Complete submission text file 0001628280-25-015057.txt   380911

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adc-20250327.xsd EX-101.SCH 1791
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adc-20250327_lab.xml EX-101.LAB 22300
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adc-20250327_pre.xml EX-101.PRE 12981
18 EXTRACTED XBRL INSTANCE DOCUMENT adc-20250327_htm.xml XML 2767
Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Filer) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39071 | Film No.: 25775326
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)